{"id":4062,"date":"2023-07-31T09:01:25","date_gmt":"2023-07-31T09:01:25","guid":{"rendered":"https:\/\/innovationisrael.org.il\/en\/?post_type=article&p=4062"},"modified":"2023-11-30T06:09:16","modified_gmt":"2023-11-30T06:09:16","slug":"personally-tailored-medicine","status":"publish","type":"article","link":"https:\/\/innovationisrael.org.il\/en\/article\/personally-tailored-medicine\/","title":{"rendered":"Personally Tailored Medicine"},"content":{"rendered":"\n
“In the future world of medicine, every person with health insurance will have his or her own clinical and demographic genetic probability profile,” declares the scientist Dr. Dekel Taliaz, founder of the Taliaz <\/strong>Health Corporation. “In the not so distant future, every one of us will have his genomic chart stored in the cloud. As soon as it is in the cloud, the technology we have developed can analyze vast amounts of data and produce individual medical value. Not just about the appropriate treatment, but also regarding the future probability of each of us to contract a particular disease and how to prevent it.”<\/p>\n\n\n\n “Health systems will use statistical probability to predict the future medical problems in public health, to implement wiser investments and to focus on more efficient prevention and treatments,” says Taliaz. Furthermore, \u201cin Israel, a conservative country with regards to the field of genetics, authorization has already been given for hospitals to begin the assembly of a bio-bank.\u201d<\/p>\n\n\n\n Dr. Taliaz and his team at Taliaz Health have developed an advanced technology that uses unique algorithms to analyze large genetic and clinical databases gathered from a large number of sources. The company, operating in the field of personalized medicine, focuses on the customization of effective drugs for brain disease. The company’s unique expertise lies in research of neuroscience and the central nervous system which, combined with innovative technologies of genetic sequencing, known as Next-Generation Sequencing (NGS), and calculative learning, accords it a significant advantage in the development of solutions for diseases related to the central nervous system and neuropsychiatric disease.<\/p>\n\n\n\n An innovative test developed by the AlgoSight Corporation is designated to assist the doctor in choosing the best and most efficient anti-depressant treatment for each patient according to his own unique genetic, clinical and demographic characteristics. Dr. Dekel Taliaz, who received his doctorate in neuroscience from the Weizmann Institute, began developing the test while completing his post-doctorate at a children’s hospital in Toronto. A team of algorithmists, geneticists, and psychiatrists recruited by the company succeeded, within a short period, in demonstrating a significant improvement in the capability to customize anti-depressant treatment for the patients already from the first prescription. This achievement that transformed it into the only such commercial technology in existence today has been validated vis-\u00e0-vis the large global databases in the fields of depression. <\/p>\n\n\n\n “We examined the predictive capability of AlgoSight versus the world’s largest database in the area of depression \u2013 the STAR*D,” explains Dr. Taliaz, “and we succeeded in proving that our algorithm predicts a reaction to treatment with anti-depressants in approximately eight out of ten patients. That is significantly higher than the current chances of success.”<\/p>\n\n\n\n Since its inception, Taliaz has enjoyed the close support of the Israel Innovation Authority and the Ministry of Economy and Industry, including some grants that have enabled the company to establish and advance its research and development. Also, conferences conducted in Israel and overseas alongside meetings with global corporations have allowed Taliaz exposure to investors and other interested parties.<\/p>\n\n\n\n <\/p>\n\n\n\n Diagnostics Within Minutes<\/p>\n\n\n\n <\/p>\n\n\n\n The Emedgene Corporation enables clinical interpretation of patients’ genomic data within only a few moments. This capability, compared to the current period of hours or even days, allows clinicians to make the correct therapeutic decisions for the unique genetics of the patient.<\/p>\n\n\n\n Einat Metzer, the company’s CEO, and founding partner tells of the development in the field and Emedgene’s contribution: “The last decade has been one of the breakthroughs in the area of genomics, in part by state-funded research in the field and also due to a decline in sequencing costs. There is a huge number of discoveries of a large clinical significance for the patients. The current estimate is that more than 80% of the population bears a unique genetic change that exists in only a small number of other patients. The medical world is undergoing a revolution with the gradual understanding that genetics is a fundamental element in the making of therapeutic decisions. Systems that analyze the unique genetic profile of each one of us will in the future become an integral part of every facet of medicine.”<\/p>\n\n\n\n “Our company,” says Metzer, “provides a decision support system for the performance of diagnostics and treatment of genetic syndromes. Using artificial intelligence technologies, learning algorithms, and revolutionary scientific methods, the platform enables geneticists and clinicians to provide accessibility to advanced genetic medicine at treatment points and helps to bridge the gap between current scientific knowledge and practical possibilities in the clinic.”<\/p>\n\n\n\n “It is true that we can sequence an entire genome at a significantly lower cost than in the past. However, the clinical interpretation of the patients’ genetic data is still largely unknown. The clinical description constitutes a bottleneck in the capability to improve accessibility to advanced genetic medicine. To date, there are only a few hundred genetic experts in the United States who possess the expertise and knowledge necessary to perform clinical interpretation. The process requires knowledge in a significant number of disciplines, and consideration of hundreds of facts from dozens of information sources.”<\/p>\n<\/div>